Synaptic dysfunction in genetic models of Parkinson's disease: A role for autophagy?

Neurobiology of Disease

Volumn 43, Issue 1, 2011, Pages 60-67

  Plowey, Edward D ^a   Chu, Charleen T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha synuclein; Autophagy; Leucine rich repeat kinase 2; Parkin; Parkinson's disease; Synaptic plasticity

Indexed keywords

DOPAMINE;

ALPHA SYNUCLEIN GENE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CHROMOSOME 12; DIFFUSE LEWY BODY DISEASE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ENDOCYTOSIS; EXCITATORY POSTSYNAPTIC POTENTIAL; GENE; GENETIC MODEL; GENETIC RISK; HUMAN; LEUCINE RICH REPEAT KINASE 2 GENE; LEWY BODY; LONG TERM POTENTIATION; NERVE DEGENERATION; NEURITE; NEUROTRANSMITTER RELEASE; NONHUMAN; OXIDATIVE STRESS; PARKIN GENE; PARKINSON DISEASE; PARKINSONISM; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW; SECRETORY VESICLE; SYNAPSE; UBIQUITINATION; UPREGULATION;

ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, MUTANT STRAINS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SYNAPSES; UBIQUITIN-PROTEIN LIGASES;

EID: 79955968946     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.10.011     Document Type: Review

References (151)

1. Abeliovich A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Alegre-Abarrategui J., et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
3. Andres-Mateos E., et al. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine). J. Neurosci. 2009, 29:15846-15850.
4. Bamber B.A., Rowland A.M. Shaping cellular form and function by autophagy. Autophagy 2006, 2:247-249.
5. Biskup S., et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
6. Boland B., et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J. Neurosci. 2008, 28:6926-6937.
7. Cabin D.E., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22:8797-8807.
8. Chandra S., et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl Acad. Sci. USA 2004, 101:14966-14971.
9. Chandra S., et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
10. Cherra S.J., et al. Review: Autophagy and neurodegeneration: survival at a cost?. Neuropathol. Appl. Neurobiol. 2010, 36:125-132.
11. Cherra S.J., et al. Regulation of the autophagy protein LC3 by phosphorylation. J. Cell Biol. 2010, 190:533-539.
12. Chung K.K., et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 2001, 7:1144-1150.
13. Clayton D.F., George J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 1999, 58:120-129.
14. Cole N.B., et al. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem. 2002, 277:6344-6352.
15. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp. Neurol. 2008, 209:5-11.
16. Crews L., et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS ONE 2010, 5:e9313.
17. Cuervo A.M., et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
18. Dagda R.K., Chu C.T. Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis. J. Bioenerg. Biomembr. 2009, 41:473-479.
19. Dagda R.K., et al. Loss of pink1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009, 284:13843-13855.
20. Doss-Pepe E.W., et al. Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J. Biol. Chem. 2005, 280:16619-16624.
21. Fader C.M., Colombo M.I. Autophagy and multivesicular bodies: two closely related partners. Cell Death Differ. 2009, 16:70-78.
22. Fallon L., et al. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J. Biol. Chem. 2002, 277:486-491.
23. Farrer M., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 2001, 50:293-300.
24. Fortin D.L., et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 2004, 24:6715-6723.
25. Fortin D.L., et al. Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 2005, 25:10913-10921.
26. Funayama M., et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 2002, 51:296-301.
27. Galter D., et al. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 2006, 59:714-719.
28. Geisler S., et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
29. George J.M., et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995, 15:361-372.
30. Gilks W.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
31. Gloeckner C.J., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 2006, 15:223-232.
32. Goldberg M.S., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 2003, 278:43628-43635.
33. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neurol. 2009, 1.
34. Greggio E., et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 2008, 283:16906-16914.
35. Greggio E., et al. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 2009, 389:449-454.
36. Groc L., Choquet D. AMPA and NMDA glutamate receptor trafficking: multiple roads for reaching and leaving the synapse. Cell Tissue Res. 2006, 326:423-438.
37. Gureviciene I., et al. Role of alpha-synuclein in synaptic glutamate release. Neurobiol. Dis. 2007, 28:83-89.
38. Hampe C., et al. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 2006, 15:2059-2075.
39. Hanson J.E., et al. Altered hippocampal synaptic physiology in aged parkin-deficient mice. Neuromolecular Med. 2010, 12:270-276.
40. Hart M.P., Xu A. Mice expressing mutant parkin exhibit hallmark features of Parkinson's disease. J. Neurosci. 2009, 29:7392-7394.
41. Hatano T., et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007, 16:678-690.
42. Healy D.G., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
43. Helton T.D., Ehlers M.D. Ubiquitin and protein degradation in synapse function. Structural and Functional Organization of the Synapse 2008, 553-597. Springer, New York. J.W. Hell, M.D. Ehlers (Eds.).
44. Helton T.D., et al. Pruning and loss of excitatory synapses by the parkin ubiquitin ligase. Proc. Natl Acad. Sci. USA 2008, 105:19492-19497.
45. Higashi S., et al. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007, 1155:208-219.
46. Hirling H. Endosomal trafficking of AMPA-type glutamate receptors. Neuroscience 2009, 158:36-44.
47. Huynh D.P., et al. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet. 2003, 12:2587-2597.
48. Imai Y., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
49. Itier J.M., et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 2003, 12:2277-2291.
50. Iwai A., et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
51. Jaleel M., et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
52. Jensen P.H., et al. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 1998, 273:26292-26294.
53. Jo E., et al. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J. Mol. Biol. 2002, 315:799-807.
54. Joch M., et al. Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol. Biol. Cell 2007, 18:3105-3118.
55. Kahle P.J., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 2000, 20:6365-6373.
56. Kirkin V., et al. A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34:259-269.
57. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
58. Kitada T., et al. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice. J. Neurochem. 2009, 110:613-621.
59. Korolchuk V.I., et al. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010, 584:1393-1398.
60. Kruger R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
61. Kumar A., et al. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS ONE 2010, 5:e8730.
62. Larsen K.E., et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 2006, 26:11915-11922.
63. Lee J.A., Gao F.B. Roles of ESCRT in autophagy-associated neurodegeneration. Autophagy 2008, 4:230-232.
64. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 2009, 18:R48-R59.
65. Li Y., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
66. Li X., et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
67. Lim K.L., et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 2005, 25:2002-2009.
68. Lin D.T., Huganir R.L. PICK1 and phosphorylation of the glutamate receptor 2 (GluR2) AMPA receptor subunit regulates GluR2 recycling after NMDA receptor-induced internalization. J. Neurosci. 2007, 27:13903-13908.
69. Lin X., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
70. Liu S., et al. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 2004, 23:4506-4516.
71. Liu S., et al. Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. Eur. J. Neurosci. 2007, 25:3583-3596.
72. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 2002, 3:932-942.
73. Luzon-Toro B., et al. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet. 2007, 16:2031-2039.
74. Macleod D., et al. The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
75. Mak S.K., et al. Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 2010, 285:13621-13629.
76. Marazziti D., et al. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc. Natl Acad. Sci. USA 2007, 104:9846-9851.
77. Maroteaux L., et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8:2804-2815.
78. Martinez-Vicente M., et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Investig. 2008, 118:777-788.
79. Mata I.F., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
80. Melrose H., et al. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006, 139:791-794.
81. Melrose H.L., et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007, 147:1047-1058.
82. Mooney R., Konishi M. Two distinct inputs to an avian song nucleus activate different glutamate receptor subtypes on individual neurons. Proc. Natl Acad. Sci. USA 1991, 88:4075-4079.
83. Mouatt-Prigent A., et al. Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia. J. Neural Transm. 2004, 111:1209-1218.
84. Munoz-Soriano V., Paricio N. Overexpression of Septin 4, the Drosophila homologue of human CDCrel-1, is toxic for dopaminergic neurons. Eur. J. Neurosci. 2007, 26:3150-3158.
85. Murphy D.D., et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20:3214-3220.
86. Narendra D., et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183:795-803.
87. Narendra D., et al. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 2009, 5:706-708.
88. Nemani V.M., et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
89. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
90. Palacino J.J., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279:18614-18622.
91. Parisiadou L., et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 2009, 29:13971-13980.
92. Peng X.R., et al. The septin CDCrel-1 is dispensable for normal development and neurotransmitter release. Mol. Cell. Biol. 2002, 22:378-387.
93. Periquet M., et al. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J. Neurochem. 2005, 95:1259-1276.
94. Perrin R.J., et al. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 2000, 275:34393-34398.
95. Plowey E.D., et al. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008, 105:1048-1056.
96. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
97. Pramstaller P.P., et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann. Neurol. 2005, 58:411-422.
98. Ravikumar B., et al. Clearance of mutant aggregate-prone proteins by autophagy. Meth. Mol. Biol. 2008, 445:195-211.
99. Rowland A.M., et al. Presynaptic terminals independently regulate synaptic clustering and autophagy of GABAA receptors in Caenorhabditis elegans. J. Neurosci. 2006, 26:1711-1720.
100. Rusten T.E., Simonsen A. ESCRT functions in autophagy and associated disease. Cell Cycle 2008, 7:1166-1172.
101. Sakaguchi-Nakashima A., et al. LRK-1, a C. elegans PARK8-Related Kinase, Regulates Axonal-Dendritic Polarity of SV Proteins. Curr. Biol. 2007, 17:592-598.
102. Sandebring A., et al. Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS J. 2009, 276:5041-5052.
103. Sarkar S., et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 2007, 282:5641-5652.
104. Sarkar S., et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 2007, 3:331-338.
105. Satake W., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
106. Sato A., et al. Parkin potentiates ATP-induced currents due to activation of P2X receptors in PC12 cells. J. Cell. Physiol. 2006, 209:172-182.
107. Seidenbecher C.I., et al. Caldendrin but not calmodulin binds to light chain 3 of MAP1A/B: an association with the microtubule cytoskeleton highlighting exclusive binding partners for neuronal Ca(2+)-sensor proteins. J. Mol. Biol. 2004, 336:957-970.
108. Senior S.L., et al. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci. 2008, 27:947-957.
109. Shimura H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25:302-305.
110. Shimura H., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293:263-269.
111. Shin N., et al. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 2008, 314:2055-2065.
112. Sidhu A., et al. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann. NY Acad. Sci. 2004, 1035:250-270.
113. Sidhu A., et al. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J. 2004, 18:637-647.
114. Simon-Sanchez J., et al. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 2006, 23:659-666.
115. Simon-Sanchez J., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
116. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
117. Smith W.W., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA 2005, 102:18676-18681.
118. Smith W.W., et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
119. Son J.H., et al. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. J. Neurochem. 2005, 94:1040-1053.
120. Specht C.G., et al. Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol. Cell. Neurosci. 2005, 28:326-334.
121. Spencer B., et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 2009, 29:13578-13588.
122. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
123. Sriram S.R., et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 2005, 14:2571-2586.
124. Staropoli J.F., et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003, 37:735-749.
125. Stefanis L., et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 2001, 21:9549-9560.
126. Tao-Cheng J.H. Activity-related redistribution of presynaptic proteins at the active zone. Neuroscience 2006, 141:1217-1224.
127. Taymans J.M., Cookson M.R. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010, 32:227-235.
128. Taymans J.M., et al. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 2006, 98:951-961.
129. Tong Y., et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl Acad. Sci. USA 2009, 106:14622-14627.
130. Tong Y., et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of {alpha}-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA 2010, 107:9879-9884.
131. Trempe J.F., et al. SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination. Mol. Cell 2009, 36:1034-1047.
132. Uitti R.J., et al. Is the neuropathological 'gold standard' diagnosis dead? Implications of clinicopathological findings in an autosomal dominant neurodegenerative disorder. Parkinsonism Relat. Disord. 2004, 10:461-463.
133. Vogiatzi T., et al. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 2008, 283:23542-23556.
134. Wang C., et al. Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem. 2005, 93:422-431.
135. Webb J.L., et al. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278:25009-25013.
136. West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 2005, 102:16842-16847.
137. Wider C., et al. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener. Dis. 2010, 7:175-179.
138. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 2010, 13:805-811.
139. Wszolek Z.K., et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995, 45:502-505.
140. Wu N., et al. Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J. Neurosci. Res. 2009, 88:1764-1776.
141. Xilouri M., et al. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 2009, 4:e5515.
142. Xiong Y., et al. GTPase Activity Plays a Key Role in the Pathobiology of LRRK2. PLoS Genet 2010, 6:e1000902.
143. Yavich L., et al. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 2004, 24:11165-11170.
144. Yi J.J., Ehlers M.D. Ubiquitin and protein turnover in synapse function. Neuron 2005, 47:629-632.
145. Yi J.J., Ehlers M.D. Emerging roles for ubiquitin and protein degradation in neuronal function. Pharmacol. Rev. 2007, 59:14-39.
146. Yu W.H., et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am. J. Pathol. 2009, 175:736-747.
147. Zarranz J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
148. Zhang Y., et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 2000, 97:13354-13359.
149. Zhu J., Chu C.T. Mitochondrial dysfunction in Parkinson's disease. J. Alzheimers Dis. 2010, 20(Suppl 2):S325-S334.
150. Zhu J.H., et al. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol. 2007, 170:75-86.
151. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.